JAZZ

Jazz Pharmaceuticals plc

262.00^post+$0.38 (+0.15%)at close +$0.00 (+0.00%)

tap the star to start your desk

as of 22:49:07 UTCnext report Nov 9 · 96d

Performance

3M+14.46%

Relationships

3 ties · EDGAR · select for source

JAZZ

JAZZ buys fromJAZZ sells to

what am I seeing?

Nodes sit closer to JAZZ when the tie is more firmly disclosed — a named revenue weight first, then high-confidence ties, then the rest. A node's glow tracks its move today: it lifts (green) when up, sinks (red) when down, and brightens with the size. Select any node for the filing sentence behind the tie.

etf exposure · n-port

MDY0.36%VTI0.02%

Earnings

just reported

Reported Aug 3, after the close · Q2 FY26The Aug 4 session moved +4.0% against ±6.8% priced in · ×0.59 what the market paid for

has moved

±4.0%

per session, last 1 reports

Open the Earnings Roomthe report · expected movement · blast radius · the record

Earnings

loading…

Event sensitivity

computed

PPIproducer pricesup 7 of 8±1.9%1.3×

FOMCrate decisionup 11 of 24±1.7%1.2×

CPROFcorporate profitsup 5 of 10±1.3%0.9×

GDPgross domestic productup 9 of 17±1.1%0.8×

PCEpersonal income & outlaysup 8 of 17±1.1%0.7×

NFPjobs reportup 4 of 7±0.8%0.6×

CPIconsumer pricesup 5 of 8±0.8%0.5×

How JAZZ has moved on past release days vs its typical ±1.4% day, and how often it closed up. Computed from daily closes — not a forecast.

Event sensitivity

loading…

News

2 stories · wire

JAZZ1dJazz Pharmaceuticals plc — 8-K filed · Item 2.02, 9.01 · SEC JAZZ1dJazz Pharmaceuticals Announces Second Quarter 2026 Financial Results · PR Newswire

News

loading…

Overview

Pharmaceutical Products

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

sector: Manufacturing
chief executive: Bruce C. Cozadd
employees: 3,200
headquarters: Ireland
listed: Nasdaq
web: jazzpharma.com

Overview

loading…